AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home iLIVER Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Editorial | Open Access

Recalibrating the evidence level in hepatocellular carcinoma: Integrating efficacy and effectiveness of immunotherapy

Han Wua,1, Xin-Fei Xua,1, Jia-Hao Lawb, Tian Yanga( )
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, National University of Hospital, Singapore 119074, Singapore

1 Han Wu and Xin-Fei Xu contributed equally to this work.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
iLIVER
Volume 4 Issue 4,
December 2025
Article number: 100200
DOI: 10.1016/j.iliver.2025.100200

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Wu H, Xu X-F, Law J-H, et al. Recalibrating the evidence level in hepatocellular carcinoma: Integrating efficacy and effectiveness of immunotherapy. iLIVER, 2025, 4(4): 100200. https://doi.org/10.1016/j.iliver.2025.100200

621

Views

1

Crossref

1

Scopus
Received: 20 October 2025
Accepted: 22 October 2025
Published: 06 November 2025
© 2025 The Author(s). Tsinghua University Press.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).